-transparent.png){kind=logo}
The in vitro activities of five new quinolones (clinafloxacin [CI-960 or PD-127391], BAY Y 3118, E-4868, E-5065, and E-5068) against 100 Bacteroides fragilis group bacterial isolates were compared with those of ciprofloxacin, ofloxacin, and sparfloxacin. Overall, E-5068 was the most active in vitro (MIC for 90% of isolates tested [MIC90], 0.25 microgram/ml); this was followed by clinafloxacin and BAY Y 3118 (MIC90, 0.5 microgram/ml). Ciprofloxacin, sparfloxacin, and ofloxacin were the least active (MIC90s, 64, 16, and 16 micrograms/ml, respectively). B. fragilis and Bacteroides caccae were more susceptible than the other members of the B. fragilis group to all of the quinolones tested.
M V Borobio, and
M Conejo, and
E Ramirez, and
A I Suarez, and
E J Perea
March 1990,
Antimicrobial agents and chemotherapy,
M V Borobio, and
M Conejo, and
E Ramirez, and
A I Suarez, and
E J Perea
March 2004,
Antimicrobial agents and chemotherapy,
M V Borobio, and
M Conejo, and
E Ramirez, and
A I Suarez, and
E J Perea
October 2002,
Antimicrobial agents and chemotherapy,
M V Borobio, and
M Conejo, and
E Ramirez, and
A I Suarez, and
E J Perea
May 1984,
Antimicrobial agents and chemotherapy,
M V Borobio, and
M Conejo, and
E Ramirez, and
A I Suarez, and
E J Perea
August 1980,
Clinical pediatrics,
M V Borobio, and
M Conejo, and
E Ramirez, and
A I Suarez, and
E J Perea
March 1990,
The Journal of antimicrobial chemotherapy,
M V Borobio, and
M Conejo, and
E Ramirez, and
A I Suarez, and
E J Perea
June 1989,
Pathologie-biologie,
M V Borobio, and
M Conejo, and
E Ramirez, and
A I Suarez, and
E J Perea
September 1992,
Antimicrobial agents and chemotherapy,
M V Borobio, and
M Conejo, and
E Ramirez, and
A I Suarez, and
E J Perea
July 2001,
The Journal of antimicrobial chemotherapy,
M V Borobio, and
M Conejo, and
E Ramirez, and
A I Suarez, and
E J Perea
August 2001,
Antimicrobial agents and chemotherapy,
